Pharmaceuticals company Mankind Pharma announced Q4FY23 & FY23 results: Consolidated Q4FY23: Revenue from Operations at Rs 2,053 crore, up by 19% YoY EBITDA at Rs 419 crore, up by 45% YoY with a margin of 20.4% PAT at Rs 294 crore, up by 52% YoY with a margin of 14.3% EPS of Rs 7.1, up by 50% YoY (FV Re 1) CAPEX of Rs 133 crore Consolidated FY23: Revenue from Operations at Rs 8,749 crore, up by 12% YoY EBITDA at Rs 1,913 crore with a margin of 21.9% PAT at Rs 1,310 crore with a margin of 15.0% EPS of Rs 32.0 (FV Re 1) Cash flow from Operations of Rs 1,813 crore CAPEX of Rs 832 crore Net cash of Rs 1,366 crore Rajeev Juneja, Vice Chairman & Managing Director, said, “The company maintained its strong growth trajectory during the year. Our domestic business continued to outperform the IPM in FY23, led by growth in chronic segments whose share has increased to 34% from 33% in FY22. Our consumer healthcare business has maintained its double-digit growth with dominant brand leadership in its categories. Our focus is on increasing the value of prescription within existing class II-IV and rural markets and increasing penetration in Metros through higher chronic presence. We also plan to leverage our brand dominance to grow our consumer healthcare business, going ahead”. Result PDF